Wave Life Sciences (NASDAQ:WVE) Stock Price Passes Below 50Day Moving Average Of $3.20

F 1

Shares of Wave Life Sciences Ltd (NASDAQ: WVE – Get Rating) fell below their 50-day moving average during trading on Friday. The stock has a fifty-day moving average of $3.20 and is trading up to $3.05. Wave Life Sciences shares last traded at $3.22 on a volume of 816,298 shares changed hands.

Wave Life Sciences shares fell 4.2%.

The stock has a market cap of $279.56 million, a P/E of -1.63, and a beta of -0.55. The company's 50-day moving average is $3.20 and the 200-day moving average is $2.48.

Wave Life Sciences (NASDAQ: WVE – Get Rating) last released quarterly earnings data on Thursday, August 11. The company reported ($0.62) earnings per share (EPS) for the quarter, falling short of the ($0.56) consensus estimate by ($0.06). The company's revenue for the quarter was $0.38 million, while analysts had expected $3.25 million. Wave Life Sciences had a negative net margin of 297.98% and a negative return on equity of 515.04%. Wave Life Sciences Ltd stock analysts. Year-to-date earnings per share are -2.24.

Hedge funds value Wave Life Sciences Institutional investors have been buying and selling shares of the company recently. And Intercept Hong Kong Ltd acquired a new position at Wave Life Sciences in the second quarter for about $37,000. Prudential Financial Inc. acquired a new position in Wave Life Sciences stock worth about $41,000 in the second quarter. In the first quarter, Mirabella Financial Services LLP acquired a new position in Wave Life Sciences stock worth approximately $44,000. Gyon Technologies Capital Management LP increased its exposure to Wave Life Sciences stock by 97.2% during the first quarter. Gyon Technologies Capital Management LP now owns 24,567 shares of the company worth $49,000 after purchasing an additional 12,106 shares in the latest quarter. Finally, in the second quarter, Cubist Systematic Strategies LLC acquired a new position in Wave Life Sciences stock worth about $67,000. 89.28% of the shares are owned by institutional investors and hedge funds. Wave Life Sciences Company Profile

See also  Life Sciences VC Firm Expands To Boston, Signs 58K SF Lease With Beacon Capital

(estimated)

Wave Life Sciences Ltd., a clinical stage gene medicine company, designs, optimizes and manufactures new stereopure oligonucleotides with PRISM, a drug discovery and development platform. He designs ribonucleic acid-targeted oligonucleotides to reduce the expression of disease-promoting proteins, or restore functional protein production, or modulate protein expression.

other indications

Get Wave Life Sciences News and Rankings Daily: Enter your email address below to receive a daily summary of the latest news and reviews from Wave Life Sciences analysts and related companies with the FREE Daily MarketBeat Newsletter.

Leave a Comment